Tarsus Pharmaceuticals Announces $200M Committed Capital from Pharmakon Advisors

Gunderson Dettmer represented client Tarsus Pharmaceuticals in its $200 million loan agreement with funds associated with Pharmakon Advisors, LP. Tarsus Pharmaceuticals applies proven science and new technology to revolutionize treatment for patients, starting with eye care.

Tarsus elected to draw $75 million on the closing date, April 19, 2024, with the remaining $125 million of committed capital available at the company’s option in three tranches through specified time windows, the last ending in December 2025. Net proceeds to the Company at closing will be approximately $40 million following the repayment of the existing credit facility, as well as fees and expenses associated with the transaction.

The Gunderson Dettmer team was led by Jay DelMonico and Ryan Gunderson and included Samuel Willie, Riley Millender and Maureen Sweeney.

Read more on Gunderson Dettmer’s work with Tarsus Pharmaceuticals

• Gunderson Dettmer Advises Tarsus Pharmaceuticals On $115.0 Million Public Offering